Gilead, Cognizant
Cognizant Expands Partnership with Gilead
Gilead is expected to enhance its efficiency through leveraging Cognizant’s expertise in AI and advanced technology applications. By deploying these solutions across the value chain, Cognizant aims to help Gilead achieve significant benefits through a newly optimized financial framework.
In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...
Gilead Sciences Inc. must face a fired employee’s lawsuit alleging its response to a co-worker’s false sexual harassment ...
Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...
Cognizant (CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (GILD) that aims to ...
The stock's fall snapped a two-day winning streak.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...
Zacks.com on MSN2d
Gilead Sciences (GILD) Stock Dips While Market Gains: Key FactsIn the most recent trading session, Gilead Sciences (GILD) closed at $93.85, indicating a -1.57% shift from the previous trading day.
Gilead Sciences Inc. closed 3.35% below its 52-week high of $98.90, which the company achieved on November 11th.
Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback